ClinicalTrials.gg
CompletedNCT00783354ATTITUDUpdated Aug 15, 2024

A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)

A Phase 4 interventional study of desloratadine and desloratadine in Urticaria and Chronic Idiopathic Urticaria, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.

Primary conditionChronic UrticariaRegistry: UrticariaReclassifiedWhy we changed it
Registry
Urticaria — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Urticaria
Why
  1. The study's listed conditions name Chronic Urticaria, a narrower term within Urticaria.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 6 months after the study started (first participant enrolled Apr 2003, registered Oct 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This double-blind pilot study was conducted to establish the best way of using desloratadine treatment to protect quality of life of chronic idiopathic urticaria (CIU) patients, after an initial 4-weeks of daily treatment: prolonging systematic daily treatment or as needed (PRN; in the case of symptoms).

02

Conditions studied

  • Urticaria
  • Chronic Idiopathic Urticaria

Browse trials for

03

In context

Chronic Urticaria Reclassified

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

This study's enrollment of 129 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.

Browse Chronic Urticaria studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Compared within Chronic Urticaria, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urticaria. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Subjects must be >= 18 years of age
  • Women of must have a negative urine pregnancy test at Visit 1 (Day 1) and must be using an acceptable method of during the study.
  • Subjects must be in general good health; ie, they must be free of any disease (other than CIU) that would interfere with study evaluations.
  • Subjects must understand and be able to adhere to visit schedules, and agree to complete the questionnaires and a diary.
  • Subjects must have at least a 6-week history of CIU (pruritus and hives) prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Subjects who used any drug in the last 30 days prior to Visit 1
  • Subjects with asthma requiring chronic use of inhaled or systemic .
  • Subjects who have been treated with any investigational antibodies for asthma or allergic rhinitis in the 90 days prior to Baseline.
  • Subjects who have been treated with intra-muscular or intra-articular corticosteroids in the 90 days prior to Baseline.
  • Subjects with urticaria that is primarily due to physical urticaria or other known etiology, except dermographism.
  • Subjects treated by drugs.
  • Subjects who have been hospitalized (including an emergency department visit) because of deterioration in their CIU within 3 months prior to Visit 1.
  • Subjects with a history of to desloratadine or any of its .
  • Subjects previously randomized into this study.
  • Subjects who have any metabolic, cardiovascular, immunological, neurological, hematological, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect subject safety.
  • Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
  • Subjects with a history of noncompliance with medications or treatment protocols.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Active comparator
    Continuous Treatment

    Drug: desloratadine

  • Experimental
    PRN regimen

    Drug: desloratadine

Interventions

  • Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (Placebo) in case of symptoms for 2 months.

    Also known as: Aerius, SCH 34117

  • Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of "rescue medication" (desloratadine 5 mg) in case of symptoms for 2 months.

    Also known as: Aerius, SCH 34117

06

What researchers measure

Primary outcomes

  1. Changes from Visit 2 to Visit 4 of Vq-derm questionnaire score and DLQI quality of life score.

    Time frame: 2 months

Secondary outcomes

  1. Estimation of disease free period after 3 months of daily treatment.

    Time frame: 2 months

  2. Average usage of rescue medication

    Time frame: 2 months

  3. Change from Visit 2 in pruritus symptom score assessed by the patient.

    Time frame: 2 months

  4. % of patients free of symptoms 2 months after Visit 4

    Time frame: 2 months

  5. Changes from Visit 2 of overall conditions of CIU

    Time frame: 2 months

  6. Discontinuation due to treatment failure

    Time frame: 2 months

  7. Investigator's assessment of response to therapy

    Time frame: 2 months

  8. Quality of disease control

    Time frame: 2 months

  9. Average consumption of treatment between Visit 2 and Visit 5

    Time frame: 4 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy. 2009 Apr;64(4):605-12. doi: 10.1111/j.1398-9995.2008.01913.x. Epub 2008 Dec 30. PubMed 19133920 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2003 to primary completion in Feb 2004, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
StartActual
Apr 1, 2003
Primary completionActual
Feb 1, 2004
CompletionActual
Apr 1, 2004
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00783354
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 31, 2008
Start date
Apr 1, 2003
Primary completion
Feb 1, 2004
Completion
Apr 1, 2004
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion